688520.SH
神州细胞
SSE · Healthcare · Biotechnology · CN
CNY 36.39
−3.96%Year over year
Reported trailing growth
- Revenue
- -43.7%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -12.7%
- Operating cash flow
- -67.2%
Forward estimates
Based on analyst estimates
- Revenue
- -72.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +15.1%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -96.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026